Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
Authors:
Open Access
- 1 May 2010
- journal article
- review article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 6, 419-429
Abstract
Peer reviewed article authored by (Margaret M Marczewski, Marek Postula, Dariusz Kosior). Read article or submit your manuscript for publishing.Keywords
This publication has 52 references indexed in Scilit:
- Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery DiseaseCirculation, 2009
- Platelet Inhibition with Cangrelor in Patients Undergoing PCINew England Journal of Medicine, 2009
- Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trialAmerican Heart Journal, 2009
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Ticagrelor — Is There Need for a New Player in the Antiplatelet-Therapy Field?New England Journal of Medicine, 2009
- Novel Antiplatelet Agents in Development: Prasugrel, Ticagrelor, and Cangrelor and BeyondAmerican Journal of Therapeutics, 2009
- Platelet activation: assessment and quantificationEuropean Heart Journal, 2001
- Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary SyndromesThrombosis and Haemostasis, 2001
- The Thromboxane Receptor Antagonist S18886 but Not Aspirin Inhibits Atherogenesis in Apo E–Deficient MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- AspirinCirculation, 2000